GRAIL Reports Growth in Galleri Test Revenue

Grail Inc ( (GRAL) ) has released its Q2 earnings. Here is a breakdown of the information Grail Inc presented to its investors.

GRAIL, Inc. is a healthcare company focused on early cancer detection using advanced technologies like next-generation sequencing and machine learning, aiming to alleviate the global cancer burden. In its second quarter of 2025, GRAIL reported a total revenue increase of 11% year-over-year, reaching $35.5 million, with its Galleri test revenue growing by 22% to $34.4 million. The company sold over 45,000 Galleri tests in the U.S., marking a 29% increase from the previous year. Despite these gains, GRAIL reported a net loss of $114 million, which includes a $28 million impairment related to Illumina acquisition intangible assets. However, the adjusted EBITDA showed a significant improvement, reducing the loss by 44% compared to the previous year. Key highlights include positive results from the PATHFINDER 2 study, which demonstrated enhanced cancer detection capabilities when Galleri was added to standard care. The company also announced a collaboration with Everlywell to expand access to the Galleri test and its availability at Rush University System for Health. Looking forward, GRAIL remains optimistic about its growth and continued advancements in cancer detection, with plans to present detailed study results at the upcoming European Society for Medical Oncology Congress.